RXRX (Recursion Pharmaceuticals) FCF Yield %: -17.05 (As of Jun. 29, 2026)


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.63
GF Value $4.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals FCF Yield %?

Recursion Pharmaceuticals RXRX +3.28% 77 FCF Yield % is -17.05 as of Jun. 29, 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, Recursion Pharmaceuticals ranks worse than 64.03% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Recursion Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-328.09 Mil, and Market Cap is $1,924.01 Mil. Therefore, Recursion Pharmaceuticals's FCF Yield % for today is -17.05%.

The historical rank and industry rank for Recursion Pharmaceuticals's FCF Yield % or its related term are showing as below:

RXRX' s FCF Yield % Range Over the Past 10 Years
Min: -29.82   Med: -15.46   Max: -1.48
Current: -17.05


During the past 7 years, the highest FCF Yield % of Recursion Pharmaceuticals was -1.48%. The lowest was -29.82%. And the median was -15.46%.

RXRX's FCF Yield % is ranked worse than
64.03% of 1415 companies
in the Biotechnology industry
Industry Median: -9.62 vs RXRX: -17.05

Recursion Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was -1,292.48%.


Recursion Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Recursion Pharmaceuticals FCF Yield % Related Terms


Recursion Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals FCF Yield % Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial -6.80 -8.21 -13.00 -14.03 -17.61

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.89 -14.93 -19.60 -8.76 -20.00

RXRX vs ABSI, GLUE, ANAB: FCF Yield % Comparison

For the Biotechnology subindustry, Recursion Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recursion Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's FCF Yield % falls into.


RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Recursion Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-380.435 / 2160.26847
=-17.61%

Recursion Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-81.439 * 4 / 1629.03103
=-20.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -17.05 mean?
Recursion Pharmaceuticals (RXRX) has a FCF Yield % of -17.05 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #906 out of 1415 companies in the Biotechnology industry, placing it in the top 64%.
Is Recursion Pharmaceuticals' FCF Yield % too high?
Recursion Pharmaceuticals' current FCF Yield % is -17.05. Based on the distribution chart, Recursion Pharmaceuticals ranks #906 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' FCF Yield % compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #906 out of 1415 companies for FCF Yield %. This places Recursion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current FCF Yield % is -17.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.15, compared to a current price of $3.63 — trading 12.7% below its estimated fair value. The current FCF Yield % is -17.05. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current FCF Yield % is -17.05 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.63 is trading 12.7% below its estimated GF Value™ of $4.15. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RXRX:

  • FCF Yield %: -17.05
  • GF Value™: $4.15 vs. price of $3.63 (12.7% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.63
Price
$4.15
GF Value